RED BLOOD CELLS ANTIGEN STABILITY AFTER DTT TREATMENT OF RED BLOOD CELL REAGENTS USED FOR IRREGULAR ANTIBODY SCREENS-Reference-Cited by-同舟云学术

RED BLOOD CELLS ANTIGEN STABILITY AFTER DTT TREATMENT OF RED BLOOD CELL REAGENTS USED FOR IRREGULAR ANTIBODY SCREENS

Published:2019-10-25 Issue:5 Volume:65 Page:800-809
ISSN:1881-3011
Container-title:Japanese Journal of Transfusion and Cell Therapy
language:en
Short-container-title:JJTC

Author:

Okuda Makoto¹,Machida Tamotsu¹,Kuribayashi Tomoko¹,Yamada Yukari¹,Hidaka Yoko¹,Yusa Takashi¹,Sobue Kouki¹,Tanaka Miri¹,Sezaki Harumi¹,Ishibashi Mizuki¹,Saito Kohei¹,Tateno Yuki¹,Shiono Noritsugu¹

Affiliation:

1. Division of Blood Transfusion, Toho University of Omori Medical Center Hospital

Publisher

Japan Society of Transfusion Medicine and Cell Therapy

Subject

Computer Networks and Communications,Hardware and Architecture,Software

Link

https://www.jstage.jst.go.jp/article/jjtc/65/5/65_800/_pdf

Reference18 articles.

1. 1) de Weers M, Tai YT, van der Veer MS, et al: Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol, 186: 1840-1848, 2011.

2. 2) Plesner T, Lokhorst H M, Gimsing P, et al: Daratumumab, a CD38 monoclonal antibody in patients with multiple myeloma-data from a dose-escalation phase I/II study. ASH Annual Meeting Abstracts, 120: 73, 2012.

3. 3) Lokhorst HM, Plesner T, Laubach J P, et al: Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med, 373: 1207-1219, 2015.

4. 4) Chapuy CI, Nicholson R T, Aguad M D, et al: Resolving the daratumumab interference with blood compatibility testing. Transfusion, 55: 1545-1554, 2015.

5. 5) Deaglio S, Canella D, Baj G, et al: Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As (2) O (3) ) on myeloma cells. Leuk Res, 25: 227-235, 2001.